Dr Lal PathLabs (DLPL) has significantly advanced its genomics capabilities by incorporating Illumina’s state-of-the-art NovaSeq X Series into its dedicated genomics division, Genevolve. This strategic move is set to enhance the speed, precision, and scale of DLPL’s genomic research and diagnostics offerings.
The NovaSeq X Series features Illumina’s next-generation XLEAP-SBS chemistry, which delivers exceptional throughput, accuracy, and environmental sustainability. The NovaSeq X Plus system can sequence over 20,000 whole genomes annually—more than double the output of earlier Illumina platforms—setting new benchmarks in high-throughput genetic sequencing.
“This investment marks another milestone in our journey toward scientific excellence and innovation,” said Mr. Shankha Banerjee, CEO of Dr Lal PathLabs Limited. “With Illumina’s latest technology, we are well-positioned to expand our genomics capabilities and make a significant contribution to India’s growing genomics ecosystem.”
Genevolve, established in 2019, has quickly become a DNA-driven center of excellence within DLPL. The addition of Illumina’s NovaSeq X Series further solidifies Genevolve’s leadership in next-generation sequencing (NGS), empowering the platform to deliver faster, AI-enabled, and highly sensitive genomic insights that can drive impactful clinical and research outcomes.